NCT01620333View on ClinicalTrials.gov

Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 29, 2000

Primary Completion Date

April 30, 2000

Study Completion Date

April 30, 2000

Conditions
DiabetesHealthy
Interventions
DRUG

biphasic insulin aspart 50

A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days

DRUG

biphasic insulin aspart 70

A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days

Trial Locations (1)

1000005

Novo Nordisk Investigational Site, Tokyo

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01620333 - Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers | Biotech Hunter | Biotech Hunter